Quarterly report pursuant to Section 13 or 15(d)

SEGMENTS (Details)

v3.21.2
SEGMENTS (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Sep. 30, 2021
USD ($)
Facility
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Segment Reporting Information [Abstract]                  
Number of FDA-licensed plasma collection facilities | Facility             3    
Number of plasma collection facilities under development | Facility             9    
Revenues $ 20,680,550     $ 10,276,358     $ 54,559,758 $ 28,263,696  
Cost of product revenue 20,295,213     11,855,464     56,897,959 42,180,319  
Loss from operations (14,437,076)     (13,800,977)     (45,182,557) (47,694,588)  
Interest and other income (expense), net (3,275,878)     (3,116,476)     (9,815,641) (8,646,186)  
Net loss (17,712,954) $ (18,905,303) $ (18,379,941) (16,917,453) $ (20,178,091) $ (19,245,230) (54,998,198) (56,340,774)  
Capital expenditures             9,835,404 9,128,359  
Depreciation and amortization expense 1,422,164     1,035,293     3,977,786 2,709,783  
Total assets 238,640,406     189,976,043     238,640,406 189,976,043 $ 207,673,394
United States [Member]                  
Segment Reporting Information [Abstract]                  
Revenues 18,265,945     8,809,667     47,368,793 24,263,110  
International [Member]                  
Segment Reporting Information [Abstract]                  
Revenues 2,414,605     1,466,691     7,190,965 4,000,586  
Corporate [Member]                  
Segment Reporting Information [Abstract]                  
Revenues 35,708     35,708     107,125 107,125  
Cost of product revenue 0     0     0 0  
Loss from operations (3,817,061)     (3,202,814)     (11,954,388) (10,390,982)  
Interest and other income (expense), net (3,297,103)     (2,848,042)     (9,735,808) (7,903,406)  
Net loss (7,114,164)     (6,050,856)     (21,690,196) (18,294,388)  
Capital expenditures             0 0  
Depreciation and amortization expense 1,174     2,236     4,571 7,117  
Total assets 27,347,259     55,612,407     27,347,259 55,612,407  
Operating Segments [Member] | ADMA BioManufacturing [Member]                  
Segment Reporting Information [Abstract]                  
Revenues 19,063,077     9,026,323     48,832,000 23,272,463  
Cost of product revenue 18,695,783     10,625,837     51,527,832 37,314,930  
Loss from operations (7,456,129)     (9,277,702)     (25,299,223) (34,606,679)  
Interest and other income (expense), net 22,822     (268,023)     (77,484) (742,336)  
Net loss (7,433,307)     (9,545,725)     (25,376,707) (35,349,015)  
Capital expenditures             3,805,472 6,619,399  
Depreciation and amortization expense 1,064,757     863,366     3,130,064 2,310,580  
Total assets 189,019,883     125,004,813     189,019,883 125,004,813  
Operating Segments [Member] | Plasma Collection Centers [Member]                  
Segment Reporting Information [Abstract]                  
Revenues 1,581,765     1,214,327     5,620,633 4,884,108  
Cost of product revenue 1,599,430     1,229,627     5,370,127 4,865,389  
Loss from operations (3,163,886)     (1,320,461)     (7,928,946) (2,696,927)  
Interest and other income (expense), net (1,597)     (411)     (2,349) (444)  
Net loss (3,165,483)     (1,320,872)     (7,931,295) (2,697,371)  
Capital expenditures             6,029,932 2,508,960  
Depreciation and amortization expense 356,233     169,691     843,151 392,086  
Total assets $ 22,273,264     $ 9,358,823     $ 22,273,264 $ 9,358,823